Why the study?
Balloon pulmonary angioplasty is a promising option for CTEPH patients ineligible for PEA or with persistent or recurrent PH after PEA, but real-life efficacy and safety data from the Greek registry were needed.
Does balloon pulmonary angioplasty improve hemodynamics and survival in patients with chronic thromboembolic pulmonary hypertension?
Does balloon pulmonary angioplasty improve hemodynamics and survival in patients with chronic thromboembolic pulmonary hypertension?
Balloon pulmonary angioplasty is an effective treatment option that significantly improves hemodynamics in patients with CTEPH who are ineligible for or have persistent pulmonary hypertension after pulmonary endarterectomy.
Balloon pulmonary angioplasty (BPA) is a novel and promising treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are ineligible for pulmonary endarterectomy (PEA) and for those with persistent or recurrent pulmonary hypertension after PEA. We present the results of BPA procedures in CTEPH patients included in the Greek Pulmonary Hypertension Registry, evaluating the real-life efficacy and safety. We analyzed data from 180 BPA procedures (2−17/patient, mean 8 ± 4/patient, 1248 dilated vessels, 0−18/session). Significant improvements were observed in mean pulmonary arterial pressure (a reduction by 44%, p < 0.001), pulmonary vascular resistance (reduction by 60%, p < 0.001), and NT-proBNP (decrease by >70%, p: 0.003), while cardiac index improved modestly (9% increase, p = 0.143). We had 37 BPA-related non-fatal complications (20.6% in all interventions), predominantly including hemoptysis. Overall survival was 91%, 75% and 62% at 3, 4 and 5 years, respectively. Therefore, BPA may be a promising therapeutic option in patients with CTEPH in Greece.
No takes yet. Share an insight, caveat, or question.
Karyofyllis et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: